We investigated the usefulness of serum pro-gastrin-releasing peptide (Pro-GRP) as a tumor marker for diagnosis, treatment monitoring and the prediction of relapse and prognosis in patients with small-cell lung cancer (SCLC). Serum samples were obtained from 127 patients with primary lung cancer (48 patients with small-cell carcinoma, 31 with adenocarcinoma, 36 with squamous cell carcinoma and 11 with large-cell carcinoma). The cutoff levels of serum Pro-GRP and neuron-specific enolase (NSE) were set at 46 pg/ml and 10 ng/ml, respectively. The specificity of Pro-GRP was significantly higher than that of NSE (Pro-GRP: 93.7%, NSE: 65.8%, p < 0.01). According to the histological type of lung cancer, the positive rates of Pro-GRP were 75% (36/48) in the small-cell carcinomas, 9.7% (3/31) in the adenocarcinomas, 5.6% (2/36) in the squamous cell carcinomas and 0% (0/10) in the large cell carcinomas. The median levels of Pro-GRP in limited disease (LD) and extensive disease (ED) patients were 199 and 295.5 pg/ml, whereas those of NSE were 14.8 and 29.3 ng/ml, respectively. The positive rates of Pro-GRP in LD and ED patients were 80.0% (16/20) and 71.4% (20/28), whereas those of NSE were 70.0% (14/20) and 89.3% (25/28), respectively. The positive rate of NSE tended to elevate with the progression of disease, whereas that of Pro-GRP was already high at an early stage. Among the 29 patients with SCLC who could be followed, the serum Pro-GRP levels of 18 responders were significantly decreased after treatment (p < 0.01), whereas those of the 11 nonresponders were not significantly different between before and after treatment (p = 0.72). In the 9 patients with SCLC who relapsed, the serum Pro-GRP levels were again elevated at the time of relapse. Seventeen patients whose ratio of the Pro-GRP level after treatment to the level before treatment was below 50% (taking the levels before treatment as 100%) survived significantly longer than did the patients whose ratio was over 50% (p < 0.01). The results of the present study suggest that serum Pro-GRP has high specificity and could be a useful marker of SCLC for treatment monitoring and prognosis.

Keywords:
Small-cell lung cancer, Tumor marker, Pro-gastrin-releasing peptide
1.
Carney DN, Marangos PJ, Ihde DC, Bunn PA, Cohen MH, Minna JD, Gazdar AF: Serum neuron-specific enolase: A marker for disease extent and response to therapy of small-cell lung cancer. Lancet 1982;i:583–585.
2.
Ariyoshi Y, Kato K, Ishiguro Y, Ota K, Sato T, Suchi T: Evaluation of serum neuron-specific enolase as a tumor marker for carcinoma of the lung. Gann 1983;74:219–225.
3.
Cooper EH, Splinter TAW, Brown DA, Muers MF, Peake MD, Pearson SL: Evaluation of a radioimmunoassay for neuron specific enolase in small cell lung cancer. Br J Cancer 1985;52:333–338.
4.
Akoun GM, Scarna HM, Milleron BJ, Benichou MP, Herman DP: Serum neuron-specific enolase: A marker for disease extent and response to therapy for small-cell lung cancer. Chest 1985;87:39–43.
5.
Esscher T, Steinholtz L, Bergh J, Nou E, Nilsson K, Pahlman S: Neuron specific enolase: A useful diagnostic serum marker for small cell carcinoma of the lung. Thorax 1985;40:85–90.
6.
Nou E, Steinholtz L, Bergh J, Nilsson K, Pahlman S: Neuron-specific enolase as a follow-up marker in small cell bronchial carcinoma: A prospective study in an unselected series. Cancer 1990;65:1380–1385.
7.
Burghuber OC, Worofka B, Schernthaner G, Vetter N, Neumann M, Dudczak R, Kuzmits R: Serum neuron-specific enolase is a useful tumor marker for small cell lung cancer. Cancer 1990;65:1386–1390.
8.
Wharton J, Polak JM, Bloom SR, Ghatei MA, Solcia E, Brown MR, Pearse AGE: Bombesin-like immunoreactivity in the lung. Nature 1978;273:769–770.
9.
McDonald TJ, Nilsson G, Vagne M, Ghatei M, Bloom SR, Mutt V: A gastrin releasing peptide from the porcine non-antral gastric tissue. Gut 1978;19:767–774.
10.
Walsh JH, Wong HC, Dockray GJ: Bombesin-like peptides in mammals. Fed Proc 1979;38:2315–2319.
11.
Knigge U, Holst JJ, Knuhtsen S, Petersen B, Krarup T, Holst-Pedersen J, Christiansen PN: Gastrin-releasing peptide: Pharmacokinetics and effects on gastro-entero-pancreatic hormones and gastric secretion in normal men. J Clin Endocrinol Metab 1984;59:310–315.
12.
Nagalla SR, Gibson BW, Tang D, Reeve JR, Spindel ER: Gastrin-releasing peptide (GRP) is not mammalian bombesin. J Biol Chem 1992;267:6916–6922.
13.
Moody TW, Pert CB, Gazdar AF, Carney DN, Minna JD: High levels of intracellular bombesin characterize human small-cell lung carcinoma. Science 1981;214:1246–1248.
14.
Yamaguchi K, Abe K, Kameya T, Adachi I, Taguchi S, Otsubo K, Yanaihara N: Production and molecular size heterogeneity of immunoreactive gastrin-releasing peptide in fetal and adult lungs and primary lung tumors. Cancer Res 1983;43:3932–3939.
15.
Yamaguchi K, Abe K, Adachi I, Kumura S, Suzuki M, Shimada A, Kodama T, Kameya T, Shimosato Y: Peptide hormone production in primary lung tumors. Recent Results Cancer Res 1985;99:107–116.
16.
Cuttitta F, Carney DN, Mulshine J, Moody TW, Fedorko J, Fischler A, Minna JD: Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature 1985;316:823–826.
17.
Maruno K, Yamaguchi K, Abe K, Suzuki M, Saijo N, Mishima Y, Yanaihara N, Shimosato Y: Immunoreactive gastrin-releasing peptide as a specific tumor marker in patients with small cell lung carcinoma. Cancer Res 1989;49:629–632.
18.
Miyake Y, Kodama T, Yamaguchi K: Pro-gastrin-releasing peptide (31–98) is a specific tumor marker in patients with small cell lung carcinoma. Cancer Res 1994;54:2136–2140.
19.
Aoyagi K, Miyake Y, Urakami K, Kashiwakuma T, Hasegawa A, Kodama T, Yamaguchi K: Enzyme immunoassay of immunoreactive progastrin-releasing peptide (31–98) as tumor marker for small-cell lung carcinoma: Development and evaluation. Clin Chem 1995;41:537–543.
20.
Yamaguchi K, Aoyagi K, Urakami K, Fukutani T, Maki N, Yamamoto S, Otsubo K, Miyake Y, Kodama T: Enzyme-linked immunosorbent Assay of pro-gastrin-releasing peptide for small cell lung cancer patients in comparison with neuron-specific enolase measurement. Jpn J Cancer Res 1995;86:698–705.
21.
Takada M, Kusunoki Y, Masuda N, Matsui K, Yana T, Ushijima S, Iida K, Tamura K, Komiya T, Kawase I, Kikui N, Morino H, Fukuoka M: Pro-gastrin-releasing peptide (31–98) as a tumor marker of small-cell lung cancer: Comparative evaluation with neuron-specific enolase. Br J Cancer 1996;73:1227–1232.
22.
Okusaka T, Eguchi K, Kasai T, Kurata T, Yamamoto N, Ohe Y, Tamura T, Shinkai T, Saijo N: Serum levels of pro-gastrin-releasing peptide for follow-up of patients with small cell lung cancer. Clin Cancer Res 1997;3:123–127.
23.
Stahel RA, Ginsberg R, Havemann K, Hirsch FR, Ihde DC, Jassem J, Karrer K, Maurer LH, Osterlind K, Houtte PV: Staging and prognostic factors in small cell lung cancer: A consensus report. Lung Cancer 1989;5:119–126.
24.
Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 1981;47:207–214.
25.
Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977;35:1–39.
26.
Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Ass 1958;53:457–481.
27.
Cox DR: Regression models and life tables. J R Stat Soc B 1972;34:187–220.
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.